Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Breakpoints are used to predict whether an antifungal agent will be clinically effective against a particular fungal isolate. They are based on a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical outcome data. For many fungus-antifungal combinations, these data might never be available. For these combinations, epidemiological cutoff values (ECVs) provide a methodology for categorizing isolates as either wild type (WT) or non-WT. In this review, we define ECVs, explain how they are generated using the CLSI methodology in standard M57, and describe how they can be used in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further effects could be due to tolerance or trailing, rather than resistance9,25–28 because the MIC was not altered at 24 h. Instead, increased growth in the presence of the drug (relative to a reference strain) was usually detected at 48 h.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [25]
In the citing paper
“Inhibitors of heat shock protein 90 (Hsp90)82, calcineurin21,25,26, target of rapamycin (TOR)83 and mutants that affect Rim10184 (a transcription factor involved in the pH response pathway) effectively eliminate tolerance and greatly increase the fungicidal activity [G] of fluconazole across a diverse set of isolates with different tolerance levels (Fig. 1E; Box 5).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [25]
Citations
Cites
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397 · cited 2×
“Finally, as mentioned above, the iterative method of ECV determination is used to generate the final ECV (4).”
MethodEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397 · cited 1×
“The first method, the visual method, simply plots the distribution of MIC values, and a reviewer sets the ECV by sight, usually 1 to 2 dilutions beyond the modal MIC value but before the distribution endpoint, disregarding any tailing of the distribution (small numbers of MICs at the high end of the distribution) (2).”
MethodPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Self-citationEspinel-Ingroff, A., Aller, A. I., Canton, E., Castañón-Olivares, L. R., Chowdhary, A., Cordoba, S., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Govender, N., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01115-12 · Cited by 251 · cited 1×
“The cryptic species (sensu lato) will not necessarily have the same wild-type MIC range or resistance profile as the parental species (sensu stricto), as was recently shown for the Cryptococcus neoformans and Cryptococcus gattii species complexes (6).”
BackgroundSelf-citationEspinel-Ingroff, A., Diekema, D. J., Fothergill, A., Johnson, E., Pelaez, T., Pfaller, M. A., Rinaldi, M. G., Canton, E., & Turnidge, J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00536-10 · Cited by 240
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
Self-citationEspinel-Ingroff, A., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Ghannoum, M., Johnson, E., Pelaez, T., Pfaller, M. A., & Turnidge, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-11 · Cited by 164
Self-citationEspinel-Ingroff, A., Colombo, A. L., Córdoba, S. B., Dufresne, P. J., Fuller, J., Ghannoum, M. A., González, G. M., Guarro, J., Kidd, S. E., Meis, J. F. G. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02456-15 · Cited by 160
Self-citationWild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154
Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00940-09 · Cited by 139
Self-citation
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute. 2016. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M57. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2016. Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
“it is probable that it has developed resistance (167).”
BackgroundSelf-citationAlarming India‐wide phenomenon of antifungal resistance in dermatophytes: A multicentre study
Ebert, A., Monod, M., Salamin, K., Burmester, A., Uhrlaß, S., Wiegand, C., Hipler, U., Krüger, C., Koch, D., Wittig, F., et al. (2020) · Mycoses · doi:10.1111/myc.13091 · Cited by 280
Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L., von Köckritz-Blickwede, M., de la Fuente-Nunez, C., O'Neil, D. A., & Angeles-Boza, A. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00326 · Cited by 132
“Thus, an ECV is not a predictor of clinical success, but allows for prediction of whether an isolate has possible resistance to a given antimicrobial (Turnidge et al., 2006; Lockhart et al., 2017).”
BackgroundBeardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Shaw, D., Singh, S., Dogra, S., Jayaraman, J., Bhat, R., Panda, S., Chakrabarti, A., Anjum, N., Chowdappa, A., Nagamoti, M. B., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01964-19 · Cited by 100
“, (i) the MIC should be determined as per standard guidelines, either by following the protocol of CLSI or the European Committee on Antimicrobial Susceptibility Testing (EUCAST); (ii) large numbers of isolates (n 100) should be included; (iii) the MIC of isolates from different laboratories ( 3) should be used; and (…”
MethodRudramurthy, S. M., Dogra, S., & Shaw, D. (2019) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_146_19 · Cited by 80
“[59] CBP depends upon several factors like the MIC distribution, pharmacokinetic/pharmacodynamic (PK/PD) data of the antifungals, and the most importantly, the outcome of disease.[59] Due to paucity of data on clinical outcome with the antifungal susceptibility data, it is hard to decide the CBP for a particular speci…”
BackgroundMethodInfluentialAntifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 88
“that resistance has developed, and it may be prudent to use a different antifungal [102].”
BackgroundBorman, A. M., Muller, J., Walsh-Quantick, J., Székely, A., Patterson, Z., Palmer, M. D., Fraser, M., & Johnson, E. M. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz568 · Cited by 75
Verma, S. B., Panda, S., Nenoff, P., Singal, A., Rudramurthy, S. M., Uhrlaß, S., Das, A., Bisherwal, K., Shaw, D., & Vasani, R. (2021) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_303_20 · Cited by 62
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
“clinical data for most of the fungal species (Lockhart et al. 2017).”
BackgroundThe Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases
Schwartz, I. S., & Patterson, T. F. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0608-y · Cited by 57
Molecular bases of antifungal resistance in filamentous fungi
Sharma, C., & Chowdhary, A. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.018 · Cited by 55
Emerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Self-citationFluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom
Borman, A. M., Muller, J., Walsh-Quantick, J., Székely, A., Patterson, Z., Palmer, M. D., Fraser, M., & Johnson, E. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00211-19 · Cited by 58
“25 to 64) 32 (8 to 64) (13) Pichia cactophila (C.”
Salsé, M., Gangneux, J., Cassaing, S., Delhaès, L., Fekkar, A., Dupont, D., Botterel, F., Costa, D., Bourgeois, N., Bouteille, B., et al. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.027 · Cited by 38
Azole antifungal resistance in fungal isolates from wastewater treatment plant effluents
Assress, H. A., Selvarajan, R., Nyoni, H. H., Ogola, H. J. O., Mamba, B. B., & Msagati, T. A. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-10688-1 · Cited by 37
“…(CBPs) are normally used as a indicative value for determining whether or not a fungus is likely to be susceptible in vivo to a concentration of an antifungal achievable at the site of infection when taken at a predetermined dosing schedule (Espinel-Ingroff and Turnidge 2016; Lockhart et al. 2017).”
BackgroundBote, K., Pöppe, J., Merle, R., Makarova, O., & Roesler, U. H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00932 · Cited by 37
Susceptibility breakpoint for Danofloxacin against swine Escherichia coli
Yang, Y., Zhang, Y., Li, J., Cheng, P., Xiao, T., Ishfaq, M., Yu, H., Liu, R., & Zhang, X. (2019) · BMC Veterinary Research · doi:10.1186/s12917-019-1783-2 · Cited by 30
Castelo‐Branco, D. D. S. C. M., Paiva, M. D. A. N., Teixeira, C. E. C., Caetano, É. P., Guedes, G. M. D. M., Cordeiro, R. D. A., Brilhante, R. S. N., Rocha, M. F. G., & Sidrim, J. J. C. (2019) · Medical Mycology · doi:10.1093/mmy/myz135 · Cited by 32
Badiee, P., Boekhout, T., Mahmoudabadi, A. Z., Mohammadi, R., Mousavi, S. A. A., Najafzadeh, M. J., Soltani, J., Hashemi, J., Diba, K., Ghadimi-Moghadam, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02539-21 · Cited by 27
“The MIC/MEC ranges, MIC/MEC50 and MIC/MEC90, MIC geometric means (MICGM), and ECVs were calculated for each Aspergillus species (17, 39).”
MethodAntifungal Susceptibility Testing and Identification
Kidd, S. E., Crawford, L. C., & Halliday, C. L. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.004 · Cited by 32
Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte Trichophyton rubrum
Jiang, Y., Luo, W., Verweij, P. E., Song, Y., Zhang, B., Shang, Z., Al‐Hatmi, A. M. S., Ahmed, S. A., Wan, Z., Li, R., et al. (2020) · Mycopathologia · doi:10.1007/s11046-020-00515-z · Cited by 23
“Since our study still could not totally fulfil the criteria of evaluation of ECV according to CLSI guidelines [58], we propose the UL-WT instead of ECV for T.”
MethodAzole-Resistant Aspergillus fumigatus: What You Need To Know
Lockhart, S. R., Beer, K. D., & Toda, M. (2019) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2019.12.003 · Cited by 18
Self-citationVélez, N., Argel, A., Kissmann, A., Alpízar-Pedraza, D., Escandón, P., Rosenau, F., Ständker, L., & Firacative, C. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1389020 · Cited by 19
Klebsiella in Wildlife: Clonal Dynamics and Antibiotic Resistance Profiles, a Systematic Review
Quintelas, M., SILVA, V. Y. N. E. D., Araújo, S., Tejedor‐Junco, M. T., Pereira, J. E., Igrejas, G., & Poeta, P. A. C. Q. D. (2024) · Pathogens · doi:10.3390/pathogens13110945 · Cited by 21
Knabl, L., & Lass‐Flörl, C. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760841 · Cited by 22
Sidrim, J. J. C., de Maria, G. L., Paiva, M. D. A. N., Araújo, G. D. S., da Graça-Filho, R. V., de Oliveira, J. S., Sales, J. A., Pereira‐Neto, W. D. A., Guedes, G. M. D. M., Castelo‐Branco, D. D. S. C. M., et al. (2021) · Microbial Ecology · doi:10.1007/s00248-021-01694-y · Cited by 18
Strategies to improve the diagnosis and clinical treatment of dermatophyte infections
Durdu, M., & İlkit, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2144232 · Cited by 17
“mostly together with allylamine resistance [44,45].”
Augostini, P., Bradley, E. L. P., Raphael, B. H., & Secor, W. E. (2023) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001788 · Cited by 15
Pontes, L., Arai, T., Beraquet, C. A. G., Giordano, A. L. P. L., Reichert‐Lima, F., da Luz, E. A., de Sá, C. F., Levy, L. O., Tararam, C. A., Watanabe, A., et al. (2024) · Journal of Fungi · doi:10.3390/jof10020122 · Cited by 15
“AF338659) using Geneious ® 8.1 (2015; Biomatters Ltd., Newark, NJ, USA).”
InfluentialParanos, P., Espinel‐Ingroff, A., & Meletiadis, J. (2024) · Journal of Fungi · doi:10.3390/jof10030214 · Cited by 14
“Thus, WT isolates may or may not respond to antifungal therapy, whereas NWT isolates are expected to be associated with clinical failure [23].”
BackgroundAntifungal resistance in yeasts from One Health perspective: A Brazilian study
Bastos, R. W., Peres, N. T. A., da Silva, K. J. G., Gouveia‐Eufrásio, L., de Carvalho, D. S., Cruz, G. S., Lucini, F., Silva, L. S., Silva, S. E., Vechi, H. T., et al. (2025) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2025.179139 · Cited by 13
Morris, A. J., Rogers, K. C., McKinney, W. P., Roberts, S., & Freeman, J. T. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.014 · Cited by 13
Jean, S., Chang, L.-W., & Hsueh, P. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.10.017 · Cited by 11
In vitro activities of nine antifungal agents against rare pathogenic fungi
Sun, L., Wan, Z., Li, R., & Yu, J. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001083 · Cited by 11
Brilhante, R. S. N., Guedes, G. M. D. M., da Silva, M. L. Q., Castelo‐Branco, D. D. S. C. M., Cordeiro, R. D. A., Sidrim, J. J. C., & Rocha, M. F. G. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.03.017 · Cited by 11
Balkrishna, A., Rastogi, S., Kharayat, B., Tomer, M., Varshney, Y., Singh, K., Kumari, P., Dev, R., Srivastava, J., Haldar, S., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15451 · Cited by 13
“Mucor spp. was treated with AMB at ECV to provide a qualitative and quantitative estimation of the relatively superior antifungal efficacy of Anu taila (Espinel- Ingroff & Turnidge, 2016; Lockhart et al., 2017).”
MethodSmith, D. J., Melhem, M. D. S. C., Dirven, J., de Azevedo, C. M. P. E. S., Marques, S. G., Lima, B. J. F. D. S., Vicente, V. A., Sousa, M. G. T., Venturini, J., Wiederhold, N. P., et al. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.01903-24 · Cited by 9
“ECVs can be a useful tool to monitor antifungal resistance, especially in patients with long-term antifungal use, which is required for chromoblastomycosis caused by Fonsecaea pedrosoi (22).”
Self-citationWild-type cutoff for Apramycin against Escherichia coli
Yang, Y., Xiao, T., Li, J., Cheng, P., Li, F., Yu, H., Liu, R., Ishfaq, M., & Zhang, X. (2020) · BMC Veterinary Research · doi:10.1186/s12917-020-02522-0 · Cited by 13
Shah, S., Vyas, H. R., Shah, B., Jangid, N. C., Choudhary, A. N., Gehlawat, T., Mistry, D., & Joshi, R. (2023) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_999_22 · Cited by 15
“[13] Limitations of this study include the use of an E-test and the lack of performing pharmacokinetic studies.”
Neto, J. F. D. C., Rocha, W. P. D. S., Makris, G., Sandoval‐Denis, M., Hagen, F., Crous, P. W., & Chaves, G. M. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012247 · Cited by 9
“5 concentrations), because of the necessity to include at least 100 unrelated strains from three independent laboratories [75].”
BackgroundSiopi, M., Leventaki, S., Pachoulis, I., Spruijtenburg, B., Meis, J. F. G. M., Pournaras, S., Vrioni, G., Tsakris, A., & Meletiadis, J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00399-25 · Cited by 10
“MTS MIC distributions were analyzed with the ECOFFinder program (available at https:// www.eucast.org/mic_and_zone_distributions_and_ecoffs) and visually (eyeball method) (51), and the WT-ULV was defined as the upper MIC value where the WT distribution ends.”
Aspergillus Section Terrei and Antifungals: From Broth to Agar-Based Susceptibility Testing Methods
Vahedi‐Shahandashti, R., Hahn, L., Houbraken, J. A. M. P., & Lass‐Flörl, C. (2023) · Journal of Fungi · doi:10.3390/jof9030306 · Cited by 8
Malassezia species: the need to establish epidemiological cutoff values
Rojas, F. D., Sosa, M. D. L. Á., Latorre, W., Mussin, J. E., Alegre, L., & Giusiano, G. (2022) · Medical Mycology · doi:10.1093/mmy/myac048 · Cited by 9
GUPTA, A. K., Mann, A., Ravi, S. P., & Wang, T. (2023) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.23.07694-6 · Cited by 8
Post-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“In research laboratory settings, strains with in vitro antifungal resistance are defined as those showing reduced susceptibility to a drug and high MICs as compared to the control or reference strain (Berman and Krysan 2020).”
MethodEvolution of antifungals for invasive mold infections in immunocompromised hosts, then and now
Weiss, Z., Little, J. S., & Hammond, S. P. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2207821 · Cited by 6
“Personalized clinical judgment is required in these scenarios, and in situations where neither breakpoints nor ECVs are available [26,27].”
BackgroundSchuetz, A. N. (2020) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2019.12.006 · Cited by 6
Pérez-Vielma, N. M., Gómez‐López, M., Martínez–Godínez, M. D. L. Á., Torres, A. L. L., Domínguez‐López, A., & Miliar-García, Á. (2024) · Clinics and Practice · doi:10.3390/clinpract14020031 · Cited by 9
“Moreover, recent studies indicate that Candida has mutagenic capabilities that allow it to develop pharmacological resistance [45].”
BackgroundMi, K., Sun, D., Li, M., Hao, H., Zhou, K., Liu, Z., Yuan, Z., & Huang, L. (2021) · Pathogens · doi:10.3390/pathogens10020105 · Cited by 5
A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species
Visvanathan, N., Lim, J. Y. A., Chng, H. T., & Xie, S. (2023) · Journal of Fungi · doi:10.3390/jof9080810 · Cited by 6
In vitro activities of six antifungal agents and their combinations against Chaetomium spp.
Sun, L., Wan, Z., Li, R., & Yu, J. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001004 · Cited by 4
Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions
Cox, V. R. V., Zuluaga, T., Gupta, A. K., Lipner, S. R., Saunte, D. M. L., Nenoff, P., Galili, E., Khurana, A., Elewski, B. E., Jabet, A., et al. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01042-1 · Cited by 4
Mercier, V., Letscher‐Bru, V., Bougnoux, M., Delhaès, L., Botterel, F., Maubon, D., Dalle, F., Alanio, A., Houzé, S., Dannaoui, É., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.11.030 · Cited by 3
Samaddar, S., Shantharaju, S. A., Kumaraswamy, B., Okade, R., Koneri, R., & Joshua, L. (2023) · IP Indian Journal of Clinical and Experimental Dermatology · doi:10.18231/j.ijced.2023.025 · Cited by 3
Nadella, R. K., Panda, S. K., Kumar, A., Uchoi, D., Kishore, P., Badireddy, M. R., Prasad, K. P., Raman, R. P., & Mothadaka, M. P. (2024) · Journal of AOAC International · doi:10.1093/jaoacint/qsae011 · Cited by 3
dos Santos, A. R., Bonifáz, A., Bombassaro, A., Machado, A. C. D. S., Rodrigues, A. M., Borman, A. M., Chakrabarti, A., Chowdhary, A., Rediguieri, B. C., Johnson, E. M., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01907-25 · Cited by 2
“The detection of isolates with non-wild-type (NWT) minimal inhibitory concentrations (MICs) enables surveillance of the emergence and spread of antifungal resistance (25).”
Self-citationSmith, D. J., van Beurden, T., Li, Y. L., Almeida‐Paes, R., Lima, B. J. F. D. S., Vicente, V. A., Lustosa, B. P. R., Walter, T. H., Neto, E. N. M., Hallur, V., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.01846-25 · Cited by 2
“ECVs can be a useful tool to monitor for antifungal resistance, especially in patients with chromoblasto mycosis caused by F. monophora , which may lead to years of antifungal treatment (22).”
Self-citationAlves, M. J., Cruz, K. S., Alves, G. S. B., Grisolia, M. E., Menescal, V. V. F., do Nascimento, I. S., Menescal, L. S. F., Pinheiro, S. B., da Silva, F. A., Trilles, L., et al. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01378-y · Cited by 2
“According to Lockhart et al. [30], the ECV can predict whether an isolate, for which there is not enough data to establish cutoff points, has acquired mechanisms of resist‑ ance to an antifungal agent with already known activity.”
Sullivan, K. V., Long, T. H., Hillesland, E., Rhoads, D. D., Wojewoda, C. M., & Zhang, S. X. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00421-24 · Cited by 2
“While ECVs do not predict clinical efficacy, prediction of acquired resistance can aid in antimicrobial selection (5).”
BackgroundHata, D. J. (2017) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2017.11.003 · Cited by 2
Antifungalgram: A unique tool to track fungal resistance
Sjogren, Z., Bushman, A. M., Holter, J., & Kumar, S. C. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf070 · Cited by 1
Cui, W., Lu, R., HUANG, S.-L., Ma, R., Wang, Q., & Liu, Y. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf264 · Cited by 2
Song, Y., Verweij, P. E., Buil, J. B., de Hoog, S., Liu, J., Guo, J., Liu, W., & Li, R. (2025) · Mycoses · doi:10.1111/myc.70118 · Cited by 1
“For these combinations, epidemiological cutoff values can provide a methodology for categorising isolates either WT or non-WT and provide some guidance for treatment [115].”
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1
Yamamoto, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824411-1.00004-1 · Cited by 2
Perfil de sensibilidade a antifúngicos de Candida lusitaniae isolada de caso de peritonite felina
Amorim, C. F., Antón, A. R. S., & Portela, R. W. (2023) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v22i3.57627 · Cited by 1
Cota, J. M., Giancola, S. E., Benavides, T. M., & Wiederhold, N. P. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00391-6 · Cited by 1
“Human datasets for posaconazole demonstrate a trend for higher response rates in treating invasive aspergillosis as posaconazole serum concentrations increase with a maximum response rate observed in the highest quartile of serum concentrations achieved at greater than 1 mg/L. [39] Interestingly, the total posaconazol…”
BackgroundMethodInfluentialCryptococcus neoformans Epidemiological Cutoff Values
Ferrara, G., Panizo, M. M., Alarcón, V., García, N., & Dolande, M. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0295-4
Cotner, S. E., & Dawson, K. L. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00208-2
Ares, Ó. M. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/15058
Larone, D. H., Westblade, D. L. F., Burd, D. E. M., Lockhart, D. S. R., Procop, G. W., & Walsh, T. J. (2023) · Wiley eBooks · doi:10.1002/9781683674436.ref
Ajao, S. O., Nelson, J. M., Yassin, A., Rosenfeld, E. B., Brandt, J. S., Monteleone, C. A., Bhatt, P. J., & Azim, A. A. (2025) · ASM Case Reports · doi:10.1128/asmcr.00142-25
dos Santos, A. R., Bonifáz, A., Bombassaro, A., Machado, A. C. D. S., Rodrigues, A. M., Borman, A. M., Chakrabarti, A., Chowdhary, A., Rediguieri, B. C., Johnson, E. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695392
“The detection of isolates with non-wild type (NWT) minimal inhibitory concentrations (MICs) enables surveillance of the emergence and spread of antifungal resistance (25).”
Self-citationSuwannasaeng, T., Hiengrach, P., Kuwatjanakul, W., Samerpitak, K., Faksri, K., Payungporn, S., Sangsiwarit, P., Budmala, P., Visedthorn, S., Ruengket, P., et al. (2026) · PeerJ · doi:10.7717/peerj.20997
“The misapplication of ECVs from other species may lead to misclassification of susceptibility and inappropriate antifungal selection, potentially compromising patient outcomes ( Espinel-Ingroff et al., 2016 ; Lockhart, Ghannoum & Alexander, 2017 ; Dannaoui & Espinel-Ingroff, 2019 ).”
Transcriptomic and phenotypic responses of Corynespora cassiicola to the JNK inhibitor SP600125
Huang, C., Jin, K., Chen, Y., Ma, Z., Cai, L., Hu, J., & Ma, D. M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11832-9
Pan, K., Song, Y., Lu, S., Li, X., Huai-qiu, H., Gong, J., Li, R.-Y., Zheng, H., Zhan, M., Zhang, S., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00650-26
Wiederhold, N. P., Bisson, C., Stevens, D. A., Hung, C.-Y., Lopez-Ribot, J. L., Patterson, T. F., & Thompson, G. R. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00744-26
“In addition, ECVs could not be calculated since these data were from a single laboratory, and results from at least three independent laboratories are required, and more than 50% of the data cannot come from one laboratory (17, 18).”
Lass‐Flörl, C., & Vahedi‐Shahandashti, R. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(26)00424-x
Winkler, M., Klauer, A. L., Edeker, S., Fedler, K. A., Rhomberg, P. R., & Castanheira, M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02559-26
“These values are not true ECVs, as they do not meet the CLSI standards that require the use of 100 unrelated isolates, testing by at least 3 separate laboratories, and no more than 50% of the total data produced by a single participating laboratory (29).”
Metadata
- Authors
- Lockhart, S. R., Ghannoum, M. A., & Alexander, B. D.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University Hospitals Cleveland Medical Center (US)
- Duke University (US)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2017-05
- Volume
- 55
- Issue
- 5
- Pages
- 1262-1268
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC5405245
- OpenAlex
- W2587942285
- Cited by
- 81
- References
- 19
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 9 · 2023: 10 · 2022: 6 · 2021: 7 · 2020: 13 · 2019: 11 · 2018: 4 · 2017: 3
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oral HIV Research Alliance (BRS-ACURE-S-11-000049-110229)
- HHS | NIH | NIH Clinical Center (R01DE024228, RO1DE17846)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- epidemiological cut-off values, molds, yeast, antifungal susceptibility breakpoints, antifungal agents, fungal isolates
- MeSH terms
- Antifungal Agents, Candidiasis, Cryptococcosis, Cryptococcus neoformans, Humans, Microbial Sensitivity Tests, Treatment Outcome, Drug Resistance, Fungal, Candida glabrata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.